Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study.
AML
MRD
induction chemotherapy
stem cell transplant
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
06 Apr 2024
06 Apr 2024
Historique:
revised:
14
02
2024
received:
21
12
2023
accepted:
16
02
2024
medline:
7
4
2024
pubmed:
7
4
2024
entrez:
6
4
2024
Statut:
aheadofprint
Résumé
For the majority of patients with acute myeloid leukemia (AML) an allogeneic stem cell transplant (SCT) in first complete remission (CR) is preferred. However, whether the number of courses required to achieve CR has a prognostic impact is unclear. It is unknown which factors remain important in patients requiring more than one course of induction to attain remission. This Acute Leukaemia Working Party study from the European Society for Blood and Marrow Transplantation identified adults who received an allograft in first CR from either a fully matched sibling or 10/10 or 9/10 human leucocyte antigen (HLA)-matched unrelated donor (HLA-A, HLA-B, HLA-C, HLA-DR, or HLA-DQ). Univariate and multivariate analyses were undertaken to identify the prognostic impact of one or two courses of induction to attain CR. A total of 4995 patients were included with 3839 (77%) patients attaining a CR following one course of induction chemotherapy (IND1), and 1116 patients requiring two courses (IND2) to attain CR. IND2 as compared to IND1 was a poor prognostic factor in a univariate analysis and remained so in a multivariate Cox model, resulting in an increased hazard ratio of relapse (1.38; 95% confidence interval [CI], 1.16-1.64; p = .0003) and of death (1.27; 95% CI, 1.09-1.47; p = .002). Adverse prognostic factors in a multivariate analysis of the outcomes of patients requiring IND2 included age, FLT3-ITD, adverse cytogenetics, and performance status. Pretransplant measurable residual disease retained a prognostic impact regardless of IND1 or IND2. Initial response to chemotherapy as determined by number of courses to attain CR, retained prognostic relevance even following SCT in CR.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Loke J, Malladi R, Moss P, Craddock C. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2020;188(1):129‐146. doi:10.1111/bjh.16355
Loke J, McCarthy N, Jackson AE, et al. Posttransplant MRD and T‐cell chimerism status predict outcomes in patients allografted with AML/MDS. Blood Adv. 2023;7(14):3666‐3676. doi:10.1182/bloodadvances.2022009493
Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high‐dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood. 1991;77(7):1423‐1428. doi:10.1182/blood.v77.7.1423.1423
Rowe JM, Kim HT, Cassileth PA, et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer. 2010;116(21):5012‐5021. doi:10.1002/cncr.25263
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345‐1377. doi:10.1182/blood.2022016867
Craddock C, Labopin M, Pillai S, et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia. 2011;25(5):808‐813. doi:10.1038/leu.2011.13
Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999;107(1):69‐79. doi:10.1046/j.1365‐2141.1999.01684.x
Walter RB, Sandmaier BM, Storer BE, et al. Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. Biol Blood Marrow Transplant. 2015;21(2):373‐378. doi:10.1016/j.bbmt.2014.09.022
Boyiadzis M, Zhang M‐J, Chen K, et al. Impact of pre‐transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients. Leukemia. 2023;37(5):1006‐1017. doi:10.1038/s41375‐022‐01738‐3
Craddock C, Jackson A, Loke J, et al. Augmented reduced‐intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. J Clin Oncol. 2021;39(7):768‐778. doi:10.1200/jco.20.02308
Hourigan CS, Dillon LW, Gui G, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38(12):1273‐1283. doi:10.1200/jco.19.03011
Araki D, Wood BL, Othus M, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease‐based definition of complete remission? J Clin Oncol. 2016;34(4):329‐336. doi:10.1200/jco.2015.63.3826
Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354‐365. doi:10.1182/blood‐2009‐11‐254441
Nagler A, Baron F, Labopin M, et al. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplant. 2021;56(1):218‐224. doi:10.1038/s41409‐020‐01005‐y
Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945‐956. doi:10.1016/j.bbmt.2005.09.004
Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft‐versus‐host disease in human recipients of marrow from HL‐A‐matched sibling donors. Transplantation. 1974;18(4):295‐304. doi:10.1097/00007890‐197410000‐00001
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457‐481. doi:10.1080/01621459.1958.10501452
Abraham SK, Arnon N, Bipin S. Summary of scientific and statistical methods, study endpoints and definitions for observational and registry‐based studies in hematopoietic cell transplantation. Clin Hematol Int. 2019;2(1):2. doi:10.2991/chi.d.191207.001
Craddock C. Transplant in AML with measurable residual disease: proceed or defer? Hematology. 2022;2022(1):528‐533. doi:10.1182/hematology.2022000353
Stelljes M, Middeke JM, Bug G, et al. Patients with relapsed/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo‐HCT) results in similar overall and leukemia‐free survival compared to intensive remission induction chemotherapy followed by allo‐HCT: results from the randomized phase III ASAP trial. Blood. 2022;140(suppl 1):9‐11. doi:10.1182/blood‐2022‐159962
Nagler A, Labopin M, Huang XJ, et al. Non‐T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplant. 2022;57(4):572‐578. doi:10.1038/s41409‐021‐01537‐x
Döhner H, Pratz KW, DiNardo CD, et al. ELN risk stratification is not predictive of outcomes for treatment‐naïve patients with acute myeloid leukemia treated with venetoclax and azacitidine. Blood. 2022;140(suppl 1):1441‐1444. doi:10.1182/blood‐2022‐169509
Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454‐464. doi:10.1056/NEJMoa1614359
Lancet JE, Uy GL, Cortes JE, et al. CPX‐351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684‐2692. doi:10.1200/jco.2017.77.6112